Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LIVN
BUYLivaNova PLC · Healthcare · United Kingdom · $4.3B · Avg Vol: $56M/d
COMPANY DESCRIPTION
LivaNova PLC is a global medical technology company dedicated to developing innovative solutions for cardiovascular and neuromodulation therapies, including heart-lung machines and vagus nerve stimulation (VNS) for epilepsy and depression. The company maintains a competitive moat through its proprietary technologies, extensive R&D, and strong intellectual property in highly specialized and regulated medical device markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.2B | 1.3B | 1.4B | 10.8% | 1.4B | 1.5B | 1.6B | 7.8% |
| EPS | -1.61 | 0.33 | 1.17 | -4.45 | 254.5% | 1.92 | — | — | — |
| Shares | 53.6M | 53.9M | 54.3M | 54.6M | +2.0% | 54.9M | — | — | — |
| Debt | 580.4M | 640.4M | 676.8M | 433.8M | -9.3% | 343.4M | — | — | — |
| Equity | 1.2B | 1.3B | 1.3B | 1.2B | -0.2% | — | — | — | — |
| Op CF | 69.9M | 74.9M | 183.0M | 254.3M | 53.8% | 245.6M | — | — | — |
| Inv CF | -38.4M | -40.3M | -48.2M | -72.9M | — | — | — | — | — |
| Fin CF | 280.1M | 21.5M | 18.6M | -285.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LIVN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LIVN | LivaNova PLC(you) | $4.3B | 79 | BUY |
| SNN | Smith & Nephew plc | $12.9B | 80 | STRONG BUY |
| NIOX.L | NIOX Group Plc | $319M | 87 | STRONG BUY |
| EKF.L | EKF Diagnostics Holdings plc | $153M | 79 | BUY |
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.8B | 87 | STRONG BUY |
| IHC.L | Inspiration Healthcare Group plc | $27M | 69 | BUY |
| HIK.L | Hikma Pharmaceuticals PLC | $4.3B | 90 | STRONG BUY |
| CTEC.L | Convatec Group PLC | $5.5B | 66 | BUY |
| CREO.L | Creo Medical Group PLC | $87M | 31 | SELL |
| SPI.L | Spire Healthcare Group plc | $1.1B | 82 | STRONG BUY |
Peer medians: ROE -3.8% · P/E 24.4x · Gross margin 55.5%